US-Japan Healthcare Connection Reverse Pitch Event
June 15, 2023
2:30–4:30 PM
Computer History Museum
1401 N. Shoreline Blvd.
Mountain View, CA 94043
Link
Fifteen Japanese corporations will deliver short presentations explaining their strategic and investment priorities to an audience of high-profile medtech startups and others at a Reverse Pitch event organized by the US-Japan Healthcare Connection as part of the Medtech Innovator (MTI) Annual Innovator Summit. The Reverse Pitch Event and MTI Summit will be held at the Computer History Museum in Mountain View, CA on June 15, 2023.
The Reverse Pitch program is designed to introduce Japanese companies that are highly interested in the healthcare/medtech industry as potential strategic partners and/or investors in early-stage medtech ventures. After the presentations, the presenting companies will be available to meet individually with Summit attendees to discuss areas of mutual interest. Companies that will be presenting are:
The tentative schedule for this event is 2:30-4:30 p.m., and attendance is limited to companies that have been pre-approved to participate. If you are interested in attending, please contact us at admin@usajapan.org.
2:00 P.M. – 2:30 P.M.
REGISTRATION
2:30 P.M. – 4:30 P.M.
PRIVATE EARLY STAGE AND PRIVATE COMPANY PRESENTATIONS

Yusuke Kogata has 20 years of experience in medtech and pharmaceutical industries, mostly as business development and sales/marketing. He joined ReCor in April, 2023 as Senior Director, Planning and Business Development, supporting the development of business strategy on a global basis, working cross functionally with the ReCor and Otsuka leadership teams, and also supporting partnering strategies with industry partners. Prior to ReCor, he led entire Otsuka RDN business as Otsuka RDN Project Leader at Otsuka Medical Devices in Tokyo, including conducting clinical studies, and developing regulatory/marketing strategies in Japan/Asia as well as global strategies with US/EU team as a global team. Prior to that, his responsibility as Senior Manager at Business Development at Otsuka Holdings was to seek investment opportunities in mainly medtech field, where he picked up ReCor and its uRDN and raised the opportunity to the management, which ended up with approval of investment and eventually acquisition of ReCor in 2018.
Company Info:
About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices Co., Ltd. focuses on the global development and commercialization of medical care products including endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).
About ReCor Medical, Inc.
ReCor Medical, headquartered in Palo Alto, CA, a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. ReCor has pioneered the use of the Paradise Ultrasound Renal Denervation (uRDN) System for the treatment of hypertension. The Paradise System is an investigational device in the United States and Japan and bears the CE mark in the EU. ReCor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise System in patients with mild-to-moderate and resistant hypertension, and has submitted an application for PMA approval in the United States with the U.S. FDA. In addition, ReCor has begun the Global Paradise System (“GPS”) Registry in the EU with plans to expand globally.

Hirobumi Watanabe is a mechanical engineer who has received a Ph.D. in Neuroscience from NYU. With expertise as both an engineer and scientist, he has made significant contributions to the fields of micro-fabrication, electrophysiology, neuro-intervention, and otolaryngology. Presently, he serves as the leader of Advanced Technology Research at Asahi Intecc USA, situated in Irvine, CA. In this capacity, he conducts a range of research projects from different angles, focusing on stroke and endovascular electrophysiology. Prior to joining Asahi Intecc, he enjoyed valuable experience working at prominent startup companies in the field of brain-machine interfaces, namely Neuralink and Kernel. These companies are recognized for their innovative contributions in this area.
Company Info:
Asahi Intecc Co., Ltd. is a leading global company at the forefront of medical device innovation, specializing in the development and manufacturing of minimally invasive medical devices. With a strong commitment to improving patient outcomes and advancing medical technology, Asahi Intecc has established itself as a renowned company with a global presence.
Asahi Intecc has played a pivotal role in revolutionizing the treatment of chronic total occlusion (CTO) through the development of high-quality guide wires. CTO is a challenging condition where blood vessels are completely blocked, requiring precise and effective intervention. With their state-of-the-art guide wires, Asahi Intecc has empowered physicians to navigate complex anatomy, cross lesions, and deliver therapeutic agents with unparalleled precision and reliability.
Building on this success, Asahi Intecc has expanded its portfolio beyond interventional cardiology, now encompassing neurology and peripheral vascular intervention as well. By combining cutting-edge engineering expertise with a deep understanding of clinical needs, Asahi Intecc continuously strives to deliver groundbreaking solutions that address the challenges faced by healthcare professionals and patients worldwide.
Leveraging their metallurgical and polymer engineering capabilities, Asahi Intecc has developed a diverse range of high-quality medical devices. This expansion includes not only guide wires but also catheters and other advanced tools designed to facilitate precise and minimally invasive procedures. By broadening their portfolio, Asahi Intecc aims to provide comprehensive solutions to healthcare professionals, empowering them to deliver optimal patient care in different medical domains.
With a strong global presence, Asahi Intecc operates subsidiaries and offices in key markets around the world, including the United States, Europe, Asia, and Latin America. This extensive network enables the company to provide timely support and solutions to healthcare providers.

Dr. Morimoto leads multiple global teams to generate new businesses in the life science industry through M&A, venture investment, and organic R&D. In addition to capital, his teams provide hands-on support to its portfolio companies with precision manufacturing, global supply chain management, business development, and fund raising. Yuichiro is on the board of many of the companies Enplas has invested in.
Prior to joining Enplas, Yuichiro worked for McKinsey & Co. for 10 years consulting to global clients in medical device and pharmaceutical industries. Yuichiro holds a Ph. D. in nuclear engineering from the University of Tokyo.
Company Info:
Founded in 1962, Enplas is one of the world’s leading independent manufacturers of high-performance custom injection-molded devices and components for various industries. Enplas’s Life Science Company offers high-performing, high-precision custom plastic devices and components to market-leading customers and growing start-ups. Our mission is to improve quality of life (of all living beings) by delivering innovative engineering and manufacturing solutions.
Enplas develops and manufactures custom consumables and devices such as reagent-loaded diagnostic cartridges, manifolds, microfluidics, fluid seals, and more. Applications include Next Generation Sequencing, digital PCR, molecular Point-of-Care Testing, single cell analysis, cell handing, Organ-on-a-Chip, biopharma manufacturing, and other In-Vitro Diagnostics and Research-Use-Only applications.
Enplas offers unique technological capabilities in microfluidics injection molding, lyophilization, liquid reagent handling and packaging, cartridge mass manufacturing, and biology on (plastic) chips. Enplas provides end-to-end services to its customers, including design development and Design-for-Manufacturability, rapid prototyping, and mass production launch with ISO13485 certified sites in the U.S. and Japan.
Enplas’ life science customers range from growing startups at the prototyping stage to multi-billion dollar global medical and diagnostic device OEMs with large volume production supplying the market. Enplas collaborates with start-up companies offering technical expertise. We wish to create new markets and products with companies focused on the molecular PoCT, liquid biopsy, single cell analysis and Organ-on-a-Chip markets, leading the market with innovation together.

As Sr. Marketing Manager at Fujikura America, Joshua Magnuson is responsible for leveraging the technical expertise and market leadership of Fujikura in electronics miniaturization, fiber optics, sensor technology and CMOS for a diverse number of industries including medical device and medical diagnostic fields. Prior to joining Fujikura, Joshua has worked as both a product marketer and product development scientist in a diverse array of fields including medical device, medical diagnostics, and biotechnology. He has worked for Abbott Laboratories and Bio-Techne, among others, as well helping to found two startup companies in the Minneapolis-Saint Paul area. Joshua has an MBA from the Carlson School of Management at the University of Minnesota and a B.S.-Biology/B.A.-History from Bethel University. He is an Affiliate Member and Board Member of the Medical Industry Leadership Institute at the University of Minnesota.
Company Info:
Fujikura is a 138 year-old company based in Tokyo, Japan. A global leader in fiber optics and electric wiring, Fujikura serves a broad range of industries including Telecommunications, Automotive, Consumer electronics and Medical Devices. Within the medical device space, Fujikura is focused on electronics miniaturization for wearable technology, fiber optics for a variety of medical imaging applications and CMOS camera modules for single-use disposable endoscopy. Our CMOS camera modules are single use disposable to lower the risk of infection and the cost of reprocessing while also being highly adaptable to a variety of designs and lighting options, allowing them to be used in a number of different specialties.

Rubal Bedi is the Global Head, Vice-President of Corporate Venture Capital at HOYA Corporation, a $45 billion multinational company, focusing on medical device, diagnostic, and digital health investments. Currently, Rubal represents HOYA on the boards of Centricity, Cryosa, and Eye-Q. Before joining HOYA, Rubal was a Director at Ascension Ventures, a hospital-based venture capital fund, where he led investments in BardyDx (acquired) and Neuronetics (IPO). Rubal previously led business development and strategy within Medtronic’s $1.6 billion Aortic and Peripheral Vascular division. While he was at Medtronic, Rubal led investments in Shockwave Medical (IPO), Lyra Therapeutics (IPO), and Arsenal Medical. Prior to his tenure at Medtronic, Rubal worked at PTV Healthcare Capital, a late-stage venture and growth equity firm. During his time there, Rubal worked with the entrepreneur in residence in the formation of Apollo Endosurgery (IPO). He received an MBA from the McCombs School of Business at the University of Texas at Austin and a BA in Economics from the University of California at Irvine. Outside of work, he enjoys spending time with his family, rooting for his Bay Area sports teams, and traveling internationally.
Company Info:
HOYA Corp is a diversified, multinational company and supplier of innovative and indispensable high-tech and healthcare products. HOYA is active in two core business segments: The Life Care segment and Information Technology segment. The Life Care segment encompasses health care areas such as eyeglass lenses and the operation of contact lens retail stores, intraocular lenses, as well as medical endoscopes, surgical equipment and artificial bones and implants. Examples of therapeutic areas of interest includes: presbyopia, myopia, glaucoma, metabolic disease, BPH, airway disease, etc. Information Technology segment focuses on electronics products for the semiconductor industry and LCD panels, glass disks for HDDs and optical lenses for digital cameras and smartphones.

Aki has been President and CEO of LINK-J since its foundation in 2016. Earlier in his career, he served as Deputy Director of METI (GOJ), Manager of Boston Consulting Group in Tokyo, Vice President/General Manager of Johnson and Johnson Japan, President of Biotronik Japan and President of Haemonetics Japan. Aki holds an MBA from Columbia University and a BS (Physics) from University of Tokyo. Aki also serves as specially appointed Professor of Tohoku University and life science related committee member of MHLW (GOJ), METI (GOJ), AMED(GOJ), Kobe City, Sapporo City, etc.
Company Info:
LINK-J (the general incorporated association Life Science Innovation Network Japan) is the largest innovation ecosystem builder in Japanese life science area. It covers a wide range of life science such as drug discovery/regenerative medicine/medical device, prevention, and longevity of life. With its about 700 members LINK-J has hosted more than 800 symposium, seminars, incubation/acceleration programs and matching/pitch events in 2022. Its facilities are in 15 buildings in a very business center of Tokyo (only 10 minutes’ walk from Tokyo Station) as well as in Osaka (west Japan) and so on.

Satoshi Iwata is in charge of Medtech business development based in the Bay Area. He is instrumental in creating business partnerships with North American and European Medtech companies to develop new businesses in the Japanese and Asian markets. Satoshi mainly focuses on cutting-edge Medtechs for acute care hospitals and other therapeutic and diagnostic solutions such as devices for OR/ICU, surgical, and robotics. Additionally, he is responsible for the BD projects of SaMD and Medtech digital transformation. Before his current role, he was engaged in sales and marketing in the Japanese Medtech field for around ten years.
Company Info:
Mitsubishi Corporation (Americas) is a wholly owned subsidiary of Mitsubishi Corporation, a global integrated business enterprise with 10 business groups that operate across virtually every industry. These include natural gas, industrial materials, petroleum & chemicals, mineral resources, industrial infrastructure, automotive & mobility, food industry, consumer industry, power solution, and urban development.
Mitsubishi Corporation operates a wide range of businesses, including medical device, supply chain, digital health, healthcare service, elderly care, living care, and so on in the healthcare space.
In the Medtech business, Mitsubishi Corporation focuses on general surgery, laparoscopic surgery, orthopedic, OB/GYN, urology, GI, ENT, respiratory/anesthesia, radiology, and cardiology. Mitsubishi Corporation has long-term partnership agreements with U.S. and European Medtech startups in the Japanese market to facilitate importing, sales and marketing, regulatory filing, quality management, etc.

Yukari Tanimoto Guevara is the Director of ICT (Information, Communication and Technology) at Mitsui Chemicals America, Inc, a diversified chemicals company with offices in San Jose and Headquarters in New York. She received her Bachelor of Arts at UC Berkeley.
Her tenure with Mitsui Chemicals started in February 2022 and prior to that, she was a Senior Market Development Manager at Kaneka Corporation overseeing thermal management materials to major Tech companies and Bio-surfactant for Personal Care Industries. Prior to that, she worked in New Business Development in various advanced tech sectors and also some projects supplying IV Bags for large Government contracts.
Mitsui Chemicals main business sectors span Mobility, Basic and Green Materials, Life and Healthcare and ICT. She is excited to meet with US-Japan Healthcare Connection Communities and StartUps to introduce Mitsui Chemicals InnoCell Product today.
Company Info
Mitsui Chemicals’ roots can be traced back to 1912 when it began producing raw material for chemical fertilizers from coal gas byproducts, the first company in Japan to do so. This undertaking significantly contributed to increasing agricultural productivity, a major social issue at the time. Later, the company evolved its technology from coal chemicals to gas chemicals, and in 1958 it built Japan’s first petrochemical complex and so provided impetus to Japan’s industry. Today, the company boasts many world-class products with sales standing at over 1,600 billion yen and with over 160 companies in 30 countries. Its business portfolio includes Life&Healthcare Solutions, Mobility Solutions, ICT Solutions, Basic & Green Materials.
Mitsui Chemicals will continue to contribute to solving social challenges with its state-of-the-art technology and by “Creating New Customer Value through Innovation”.
More information can be found at https://www.mitsuichem.com

Hiroyoshi Take, Ph.D. is responsible for tech-scouting, evaluating, structuring partnerships, and possible investment in digital health technologies.
Company Info
Nitto Denko is a global company specializing in advanced materials and technologies, making significant strides in various industries including healthcare. With a rich history spanning over 100 years, Nitto Denko has continuously driven innovation and contributed to the betterment of society.
Nitto Denko is working in two important areas of healthcare: heart failure and mental health. These diseases affect millions of people worldwide, and Nitto Denko is committed to developing cutting-edge solutions to improve the quality of life for patients.
We have focused on developing a patch-type wearable device for diagnosis in the field of heart failure. Through extensive research and collaboration with medical experts, pilot sales are being conducted in Japan.
Furthermore, Nitto Denko recognizes the urgent need to address mental illness, which has a profound impact on individuals, families, and communities. Nitto Denko is developing a wearable device sensor that detects mental health conditions. The device is intended to be used, for example, for monitoring during counseling sessions.
Nitto Denko is committed to providing comprehensive solutions that address the unmet needs of patients suffering from heart failure and mental illness. We are looking for partners who together aim to make a positive difference in the lives of people around the world.

Toshio Fujimoto, MD. MBA. is the CEO of iPark Institute, Co. Ltd., which aims to develop innovation ecosystem of life science at Shonan Health Innovation Park (iPark) in Japan. Shonan iPark was opened in April 2018 as a part of Takeda Pharmaceutical and Dr. Fujimoto has led the initiative as General Manager since he joined Takeda in Dec 2017. In April 2023, iPark Institute was spun off to operate the business of science park.
Prior to joining Takeda, he worked at Eli Lilly Japan for over 10 years to oversee the whole R&D function as Vice President, Medicines Development Unit. Earlier in his career, he was a thoracic surgeon and worked in renowned hospitals in Japan, Germany, and the US.
He received his M.D. from Kyoto University and his M.B.A. from Kobe University.
Company Info:
iPark Institute Co., Ltd. was established in April 2023 to build and develop life science ecosystem in Japan. It succeeded its operation from Takeda Pharmaceutical, one of the biggest global pharmaceutical companies originated in Japan. Takeda has located its research center for drug discovery in Shonan since 2011, and transformed it into a hub for open innovation, called Shonan Health Innovation Park (iPark) which started its operation in 2018.
With a vision to bring innovative ideas to society, iPark has been engaging in several core activities to catalyze innovation, which are to provide high quality research service and facility, to attract diverse types of companies, to facilitate their interactions, to incubate startups, and to provide platforms for collaboration. As a result, more than 100 tenant and 60 membership companies (as of 04.2023), from early startups to big companies, are gathering at iPark. Majority of them are biopharmaceutical companies, while university offices, companies from food and cosmetic industries, MedTech companies, AI/Dx companies are also included. They are forming a big science community to share ideas and experiences daily, which leads to many collaborative research projects, newco generation, and businesses partnerships at iPark.

Takahito Ishikawa is a manager for Medical & Bio Products at Sumitomo Plastics America, a subsidiary of Sumitomo Bakelite. He has experiences in R&D and business development for medical devices as well as R&D for plastics. He is currently seeking innovative companies to collaborate with in the field of medical devices and bio products.
Company Info:
Sumitomo Bakelite offers chemical-based products including plastics, medical devices and bio products. In the medical device industry, our subsidiary, SB-KAWASUMI LABORATORIES is engaged in research, development, manufacturing and sales of medical devices for gastrointestinal endoscopic/endovascular treatment, surgical drainage, dialysis, blood sampling and transfusion in Japan and other countries. Our manufacturing sites provide quality products globally under a quality management system which meets each country’s strict pharmaceuticals and medical device standards. We seek the partners with whom we can collaborate in distribution in Japan or manufacturing to continuously contribute to the improvement of Quality of Life.

Kenjiro Fujio
RDCA is a wholly owned subsidiary of Sysmex Corporation, focused on realizing preventive medicine and bringing new clinical applications from the US to the rest of the world via the Sysmex organization.
Kenjiro leads growth initiatives related to digital health and digital therapeutics. In that capacity, he is particularly eager to meet with early-stage companies developing innovative new digital diagnostic and therapeutic solutions.
Before joining Sysmex, he held a position at Omron Healthcare, where he led the global development of the remote patient monitoring system business. He received his bachelor’s degree in Environment and Information studies from Keio University and is now pursuing Master of Business Administration from Indiana University, Kelley business school.

Shrey Singh
Shrey is determined to uncover latent needs of patients to solve unmet needs in healthcare. A former program manager in Sysmex Japan, now focusing on digital health strategy in the Bay Area.
Background:
Bachelor of Engineering, Electronic Engineering, Hong Kong University of Science and Technology
Former Co-founder of Glaulens, a wearable soft contact lens with embedded circuit to detect changes in IOP (intraocular pressure) to avoid missed glaucoma diagnoses.
Company Info:
Sysmex corporation is a leading IVD company from Japan specializing in high throughput blood and urine testing. The digital healthcare section is based in the bay area in California.
We are interested in startups in the following areas.
-Business domain
Digital Health, Digital Medicine, Digital Therapeutics, Digital Biomarkers, Home Care
-Disease
CNS diseases(e.g. Dementia), Cardiovascular diseases(e.g. HF, Stroke), Life style diseases(e.g. Hypertension)
-Startups needs
KOL networks, Assist for regulatory approvals, clinical studies, and global market entries

Yosuke Matsubara is a Business Development and Licensing Manager at Teijin Pharma, a Tokyo-based company that operates in both pharmaceuticals and medical devices. With over 10 years of experience in drug development at Teijin Pharma, Yosuke’s expertise lies in clinical trials, negotiating with regulatory agencies for approval, and project management.
Yosuke is responsible for licensing-in both medical devices and drugs, focused on exploring potential collaborations and partnerships with startups in the medical device and drug spaces. Teijin Pharma’s medical device business is limited to home-use devices, and its businesses are limited to the Japanese market. Many of the company’s available products in Japan are from overseas, and licensing-in is an important activity.
Yosuke earned his Ph.D. degree in medical science before joining Teijin Pharma in 2008. Prior to joining Teijin Pharma’s medical device business in 2021, he gained extensive experience in drug development.
Company Info:
Teijin Pharma is a healthcare company focused on delivering innovative home-use medical devices and pharmaceuticals to the Japanese market. With a strong emphasis on patient support, we have established an extensive service network throughout Japan, enabling us to provide direct delivery, education, setup, and maintenance services for our medical devices in the comfort of patients’ homes. Our portfolio includes cutting-edge technologies in respiratory, orthopedic, metabolic, and other therapeutic areas. We are actively seeking to expand our medical device business, particularly in the area of psychiatric diseases like depression, ADHD, and PTSD. Additionally, we are interested in partnering with companies developing home-use treatment medical devices and monitoring devices for early detection of exacerbations to prevent readmissions. In the respiratory disease area, we have a leading market share in Japan for our home oxygen concentrator and CPAP devices, providing life-changing benefits to patients with COPD and sleep apnea. To ensure timely and efficient support for our patients, we have a call center that is available 24/7. Our highly trained and knowledgeable staff are always available to answer questions and provide assistance, helping to ensure that our patients receive the best possible care.
We have a strong track record in regulatory approvals with the Japanese agency, and our products are reimbursed in Japan. We are always interested in exploring partnerships with innovative companies in the healthcare space, and we can help distribute your device in Japan through our established channels. As a core group company of Teijin, we have access to extensive resources and expertise in research and development, allowing us to continue to drive innovation in the healthcare industry and shape the future of patient care. We also have a venture capital fund in the US, focused on early-stage startup investments for companies seeking investment opportunities.

Yushin Yazaki is currently the Director of Venture Arm at Terumo Corporation. Previously, he held the position of Global Products Manager in the same company. Yushin received his Master’s degree from Hitotsubashi ICS (Hitotsubashi University Business School) and his PhD in Materials Science from Waseda University.
Company Info:
Terumo has three companies; Cardiac and Vascular Company, Blood and Cell Technologies Company, and Medical Care Solutions Company.
The businesses of the Cardiac and Vascular Company involves the heart, lung, and brain, and treatment of blood vessel diseases throughout the body. The company provides interventional devices, oxygenators and heart-lung machines, and surgical grafts and stent grafts globally.
Blood and Cell Technologies Company provides collection and processing sets and other supplies for efficient blood processing. Additionally, the company provides devices that use centrifugation and separation technology to collect or remove specific blood components, enabling a variety of blood treatment solutions. In the fields of cell and gene therapy, the company provides research institutions and pharmaceutical companies with instruments and services that enable high-quality, large-scale production of cell products to support the creation of new therapies.
Different from above two Companies, Medical Care Solutions Company is doing the business broadly, but mainly focusing Japanese market. The company offers a variety of expertise to address the needs of those in medical care settings, including medical safety, in-facility infection prevention, and cost control. These include advanced infusion system, peritoneal dialysis, infection prevention and environmental control, preoperative and oncological products. Chronic diseases are also their focus. The company provides the products in the areas of diabetes care, heart failure care, and vital sign management in hospital and home settings. Additionally, the company offers solutions to pharmaceutical companies globally by proposing new drug delivery devices. They leverage its material technology optimized for the characteristics of each drug and utilizes advanced manufacturing technology to design and produce drug-device combination products. Through alliances with pharmaceutical companies, they provide a total solution from clinical trial drug manufacture to full commercialization.

After working as an MR at Dainippon Sumitomo Pharma, Mr. Masaru Fukunaga worked as a consultant at Eliment HRC, a headhunting company specializing in the medical industry (life sciences), and contributed to the promotion of the medical device business as a division manager.
He was involved in various projects such as executive search at a UK-based consulting firm specializing in life sciences, and met more than 500 medical business talents per year. He has knowledge of medical business from upstream to downstream, from drug discovery to regulatory submission and launch, and has relationships with various medical business personnel and pharmaceutical/medical device companies.
Later, he established xCARE, Inc. to solve problems and promote innovation in the medical business.
Company Info:
xCARE (Cross Care) provides hands-on support and recruitment support in the field of medical business (pharmaceuticals, MedTech, regenerative medicine). There are more than 150 experts with various skills who are registered on xCARE’s human resources platform. xCARE’s hand’s on support enables to cover a wide range of tasks, by forming a team with such experts, in the area of product development and commercialization including regulatory affairs, clinical trials, and quality systems. This service is greatly appreciated by the companies from many countries (particularly start-ups) that are not ready to hire personnel but need medium/short-term resources to develop the business in Japan. xCARE also supports Japanese companies to develop the business outside Japan collaborating with the experts in each country. Please contact us for more information.
Melissa McCool is the Chief Operating Officer at Ellipsis Health, where she shapes strategy, leads implementation, and brings Sage’s voice to life. She previously served as Chief Product Officer. Before joining Ellipsis, Melissa founded and led two behavioral health companies built around the clinical STI program she developed. Outside of Ellipsis, she continues to treat trauma patients and finds joy in the ocean, modern dance, and time with her family.
ClariMed is a human-centered medical device development and regulatory services company. We work with medical product development teams in MedTech and pharma, with human factors at the core of everything we do, so safety and usability are built in from the start.
What we offer across the product lifecycle:
How we deliver:
Vantiq provides a real-time AI orchestration platform that connects data, systems, devices, and AI to enable intelligent, automated operations. By processing events as they happen and coordinating AI agents and workflows in real time, Vantiq helps organizations make faster decisions, improve operational efficiency, and build innovative digital solutions without replacing existing infrastructure.
In healthcare, Vantiq enables solutions that integrate electronic health records (EHRs), clinical data, and AI to streamline care coordination and clinical workflows. By coordinating multiple AI agents to continuously monitor conditions and predict potential issues, Vantiq enables care team members to receive early alerts before situations deteriorate, giving them time to prepare and take proactive action.
Beyond healthcare, Vantiq supports digital transformation across industries including manufacturing, mobility, and critical infrastructure.
Website: https://vantiq.com/
Tanabe Pharma Corporation is a Japan-focused, innovation-driven pharmaceutical company guided by its mission, “Creating hope for all facing illness.” Founded in 1678, the Company is one of Japan’s oldest pharmaceutical companies and is committed to addressing unmet medical needs through R&D, business development, and strategic partnerships with the aim of improving the lives of patients. Building on its long heritage, Tanabe Pharma is now embarking on a new chapter of transformation, with an ambition to become a more agile and globally connected innovator. The Company is strengthening its engagement with the global science and innovation community, including biotech companies, venture capital, academia, and other partners, to identify promising science and accelerate the delivery of innovative medicines to patients in Japan. This direction reflects the company’s current emphasis on stronger global science engagement, BD&L, and more integrated R&D. Tanabe Pharma aspires to serve as a bridge between the global innovation ecosystem and Japan through combination of deep knowledge of the Japanese healthcare landscape with access to global innovation, translating breakthrough science into meaningful value for patients.
Orrick is a global law firm with offices in 25+ markets worldwide, including a team in Tokyo. The firm is focused on serving the life sciences & healthtech, technology & innovation, energy & infrastructure, and finance sectors. We provide industry leaders and disruptors in life sciences & healthtech with multi-dimensional solutions, helping them protect their innovations, invest, partner, scale and get to market. We act for more than 800 life sciences & healthtech clients, including companies based in Japan. Our clients include 7 of the top 10 global biopharma leaders, hundreds of venture-backed companies, and leading investors in these sectors.
Website: https://www.orrick.com/
Name: Mittal Consulting
Website: mittalconsulting.com
What we do: Regulatory and Reimbursement Services for Novel Medical Devices
Headquarter: Portland, Oregon, USA
Mittal Consulting | Your Strategic Partner for US Market Entry
Mittal Consulting is a US-based boutique regulatory and reimbursement consulting firm helping innovative medical device companies successfully navigate the FDA path to the US market.
For Japanese MedTech companies looking to enter or expand in the United States, understanding FDA requirements, clinical evidence expectations, and reimbursement pathways is critical to successful commercialization. Mittal Consulting provides the expertise and strategic guidance to navigate these complexities with confidence.
Our services include FDA regulatory strategy, pre-submissions, 510(k), De Novo, PMA, clinical evidence planning, reimbursement strategy, and US market access. We work with innovative medical technologies across Cardiovascular, AI/SaMD, Neurotechnology, Ophthalmology, Surgical robotics, Diagnostics, and other specialties.
We are proud to support the US-Japan MedTech ecosystem and look forward to connecting with Japanese innovators seeking a trusted, long-term partner for US commercialization.
Visit our booth at the US-Japan Healthcare Week 2026 to meet our team and explore your pathway to the US market.
GiGOOO is a Japanese technology company based in Fujisawa, Kanagawa, combining software engineering, artificial intelligence, and consulting to help organizations put digital transformation into practice.
Our services cover business process analysis, custom software development, AI implementation, workflow automation, quality assurance, and ongoing operational support. We work with clients from initial planning and proof of concept through deployment, while providing training and support to help their teams use and maintain new solutions. We also help bring overseas technologies to the Japanese market through localization and implementation support.
For healthcare and life sciences organizations, our capabilities offer a starting point for exploring practical challenges such as administrative workload, fragmented information, and the adoption of new digital tools. Our focus is on translating business needs into systems that people can use in their everyday work.
As a sponsor of the US-Japan Healthcare Conference, GiGOOO looks forward to connecting with companies, researchers, and innovators interested in applying AI and software engineering to their next stage of digital transformation.
Website: https://www.gigooo.com/
Axcelead Drug Discovery Partners is a Japan-based global provider of drug discovery solutions, established in 2017 as a spin-out from Takeda.
Our Integrated Drug Discovery Services provide seamless, end-to-end support across all functions, advancing programs from target validation through IND-enabling studies. We offer expertise across a wide range of therapeutic areas, including neuroscience, oncology, cardiovascular and metabolic diseases, immunology and inflammation, and musculoskeletal disorders. Leveraging legacy data from over 1,000 research projects inherited from Takeda—including hit and lead compounds as well as extensive biological datasets—we help clients accelerate their drug discovery programs and make more informed development decisions.
In addition to our integrated services, each of our core technology platforms is available as a standalone service. This flexible model enables clients to benefit from world-class science, whether through a fully integrated program or individual, best-in-class services tailored to their specific needs.
Website: https://www.axcelead.com/
Tomoyoshi Koyanagi is Director of BioLabs Japan, where he works to accelerate the commercialization of university-based medical innovation and build a stronger bridge between Japan and the global biotech ecosystem. He develops end-to-end infrastructure that translates basic science into clinical applications, investable assets, and new ventures. He leads the implementation of SPARK in Japan, based on Stanford University’s translational research program, and organizes HVC KYOTO, an English-language pitch platform where startups receive strategic feedback from global pharmaceutical executives and investors evaluate opportunities alongside real-world commercialization strategies. In 2025, he co-founded BioLabs Japan and BioLabs Academy in partnership with BioLabs, a leading U.S. life science incubator operator, and has served as Director since September 2026. He is also a Collaborative Researcher at Kyoto University’s Growth Strategy Headquarters. He earned his Ph.D. from Osaka University and conducted postdoctoral research at Stanford University under Dr. Daria Mochly-Rosen, founder of SPARK.
Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Elton
represents both public and private enterprises as their outside general counsel and serves as a
key strategic advisor from their inception throughout their life cycle. He advises on complex
venture capital and corporate finance transactions, corporate law and governance, mergers and
acquisitions, and public offerings. Elton has a particular focus on companies in the medical
device, biotechnology, pharmaceutical, diagnostic, and digital health sectors and serves as coeditor of The Life Sciences Report, a semi-annual newsletter on the life sciences industry
published by the firm. He is also a board member and founder of US-Japan Medtech Frontiers, a
nonprofit corporation that has hosted annual cross-border healthcare conferences in Japan for
the past decade. In addition, Elton is a frequent guest lecturer at universities, industry and
trade group conferences, accelerators, and incubators.
Ayumi Nakatani is a Deputy Review Director in the Office of New Drug V at the Pharmaceuticals and Medical Devices Agency (PMDA), where she is responsible for the review of anticancer drugs. After completing her graduate studies in pharmaceutical sciences, she worked as a researcher at a pharmaceutical company before joining PMDA. She has since been involved in the review of new drug applications and has served in her current position since April 2025.
Yooya Hwang has extensive experience working across multiple medical device companies to establish and grow dedicated market spaces in Japan. As the Business Development Head of Japan at Subtle Medical, he brings deep expertise in the radiology field and robust industry networks throughout the country. Passionate about artificial intelligence, Yooya is dedicated to driving and accelerating AI adoption within the healthcare sector.
Seth Flaum is a strategic adviser to life sciences and healthcare technology companies on high-stakes transactions and growth initiatives worldwide. For more than 25 years, he has represented public and private clients across the life sciences life cycle, from startups to multinational pharmaceutical companies, including biotechnology, medical device, diagnostics, digital health, and artificial intelligence (AI) companies, as well as private equity funds. He leads transactions such as licenses, asset purchases, collaborations, and joint ventures, together with research and development (R&D), commercialization, co-promotion, profit-sharing, manufacturing, and supply agreements.
Much of Seth’s work is cross-border, spanning the United States, Europe, Asia, and the Middle East. He is widely recognized for his Japan practice, advising Japanese companies expanding abroad and companies doing business in Japan with Japanese partners.
Seth previously served as in-house counsel at a large global pharmaceutical company, where he led a team of lawyers and business professionals responsible for intellectual property and business development. That experience gives him a firsthand understanding of the commercial realities that drive dealmaking.
Seth’s practice extends to public and private mergers and acquisitions (M&A), with particular experience in earnouts and contingent value rights agreements, as well as antitrust filings, US Securities and Exchange Commission and Financial Industry Regulatory Authority matters, and corporate governance.
Additionally, Seth counsels senior executives and serves as outside general counsel to companies seeking day-to-day support in running a life sciences business. His combination of international perspective, sector experience, and in-house insight allows him to guide clients from the earliest stages of an opportunity through execution and beyond.
Thomas Alkeskjold is co-founder and CEO at Optheras. He has a background as innovation manager at A.P. Moller-Maersk, and as engineering manager and director of R&D at NKT Photonics. He has more than 20 years of experience in the field of optics and photonics, developing, maturing and bringing to market new laser technologies. He has a M.Sc. in Electrical Engineering and a Ph.D. in Laser and Fiber Optics Technology from the Technical University of Denmark.
Optheras A/S is a Danish medtech company, established in June 2022. The company specializes in developing laser-based technologies for the treatment of superficial bladder cancer, focusing on laser coagulation to target and treat non-invasive tumors. Their innovative approach aims to provide less invasive, low-pain alternatives to traditional surgical procedures, enabling treatments in office settings rather than operating rooms.
Peter Bauer is a medical device executive with three decades of experience advancing innovation in cardiology and heart failure management. His work spans implantable therapeutic devices and non-invasive cardiac diagnostics, with a focus on improving patient outcomes and quality of life.
Peter has held senior leadership roles at BIOTRONIK and Inovise Medical, bringing experience in both established medical device companies and innovative startups. At Inovise, he helped position the company as an international pioneer in non-invasive cardiac monitoring. His expertise encompasses business development, operations, clinical studies, product development, and early-stage commercialization.
As Chief Executive Officer of VisCardia, Inc., Peter leads the company’s strategy and operations, advancing a novel therapeutic approach for heart failure patients who remain symptomatic despite guideline-directed medical therapy. Under his leadership, VisCardia is advancing its technology toward commercialization and pursuing a $10 billion market opportunity.
In 1993, Takahashi began his career as a researcher at a pharmaceutical company. Following a series of mergers, he became affiliated with Bayer Yakuhin, Ltd., where he led projects focused on new drug discovery and validation. During this time, he also contributed to regenerative medicine and iPS cell research as a senior researcher at the Kobe Research Center.
He later served as manager of cardiovascular project management within Bayer’s Product Development Japan division, overseeing cardiovascular projects. He was subsequently appointed head of the Primary Care Department in Medical Affairs Japan. In 2014, he was appointed head of Bayer’s Open Innovation Center Japan. In this role, he not only established the center but also led the first comprehensive partnership with Kyoto University. He also launched Bayer’s third startup incubator, CoLaborator Kobe. As a member of the Bayer Open Innovation Global Leadership Team, he played a key role in advancing open innovation in Japan.
In 2022, Takahashi left Bayer and joined LINK-J as President & COO, where he has been contributing to the development of life science ecosystems in Japan. In April 2026, he was appointed Chief Executive Officer.
As a serial entrepreneur, innovator, and scholar, I have dedicated my career to seeking fundamental improvements in the quality and development of the Medical Devices Industry. As an entrepreneur and innovator, I founded five medical device companies ReVascular Therapeutics (Acq. Boston Scientific), PROSTIS, PerfusionRx, GVMED Incubator, and currently PercAssist CEO, and served as a consultant to over 50 companies in Silicon Valley. As a part of my mission to continue to inspire future generations to make advancements in Biotechnology, I served on the Board of Santa Clara University’s School of Bioengineering, as well as an Associate Professor of Bioengineering at Santa Clara University’s Bannan Graduate School of Engineering. In addition to this, I serve as a UCSF Surgical Consortium member, UCSF Catalyst Medical Innovation Program, BMES Executive Committee Founding Member, Simon Fraser School of Bioengineering Innovation Boulevard EiR. BC, Canada. Speaker at The University of Tokyo Graduate School of Pharmaceutical Sciences, Shanghai Jiao Tong University School of Pharmacy.
In response to changing clinical needs, I assess new clinical business opportunities worldwide and develop new technologies that are responsive to the dynamic nature of the health needs of the population. My hands-on experience resides in bringing new technologies from paper to full commercialization under the “Vision and Execution” philosophy.
Our unique proximity to Silicon Valley provides a wealth of opportunities for innovation like no other place in the world. I am always searching for the next frontier to improve clinical therapies and reduce healthcare costs.
As a partner of Saisei Ventures, Dr. Saito is responsible for Japan operations including company creation, integrating Japanese science and technology with the Western ecosystem. Prior to joining Saisei, he started career as a research scientist at Astellas Pharma Inc. and then as a Senior Manager of Business Development and as a Senior Investment Manager at Astellas Venture Management, a CVC arm based in Silicon Valley, USA, where he was a lead role for deal process, due diligence and transactions for venture investments in RNA therapeutics, cell and gene therapy. He was providing business support to portfolio companies based on the expertise, experience, and global network. Prior to joining Astellas, he was a Visiting Fellow at the Institute of Medical Science, University of Tokyo, and a Research Fellow of the Japan Society for the Promotion of Science. He received his B.S. in Biotechnology and M.S. and Ph.D. in Biomolecular Molecular Engineering from Tokyo Institute of Technology.
Yamada joined NVIDIA Japan in 2004 following experience at a Japanese semiconductor company. After leading business development across PCs, workstations, and embedded systems, Yamada launched NVIDIA’s healthcare business and AI startup acceleration programs in Japan in 2016. Since 2021, Yamada has been dedicated to empowering healthcare developers, driving technical partnerships and enablements across AI medical devices, genomics, AI computational drug discovery, and digital health.
Richard N. Larsen, a career member of the Senior Foreign Service, currently serves as Consul General at the U.S. Consulate General in Osaka-Kobe, Japan. His prior work in Japan includes serving as Deputy Chief of the Political-Military Affairs Unit at the U.S. Embassy from 2016 to 2019. Richard’s other overseas assignments include postings in Islamabad, Pakistan, as well as multiple assignments in China and Iraq.
In Washington, Richard served in the State Department’s Bureau of East Asian and Pacific Affairs as Chief of Staff in the Office of the Assistant Secretary and as Director of the Office of Regional and Security Policy.
Before joining the State Department, Richard served in the U.S. Army. He is a graduate of the U.S. Army War College and Brigham Young University Law School. Richard is married and is joined in Japan by his wife; they have four grown children.
リチャード・N・ラーセン ― 在大阪・神戸米国総領事館総領事
*下記の日本語文書は参考のための仮翻訳で、正文は英文です。
リチャード・N・ラーセンは、国務省の上級外交官であり、在大阪・神戸米国総領事館総領事を務める。2016年から2019年までは、在日米国大使館の政治部安全保障課に課長補佐として勤務した。また、パキスタンのイスラマバードでの勤務経験もあり、中国とイラクへは複数回赴任している。
ワシントンでは、国務省東アジア・太平洋局で、次官補室の首席補佐官や地域・安全保障政策室長を務めた。
国務省入省前は、陸軍に所属。米陸軍戦略大学、ブリガム・ヤング大学法科大学院を卒業した。日本には妻と赴任。成人した4人の子どもがいる。
After working as a postdoctoral researcher at the University of Tokyo, Dr. Hayashi engaged in drug discovery research in the field of neurological diseases (e.g., Target ID/validation, development of in vitro assay systems) as a researcher at Merck Research Laboratories, USA and Toray Pharmaceutical Research Laboratories, Inc. in Japan. After working as COO at Hamamatsu Pharma Research USA, Inc. in San Diego, U.S., he joined Open Innovation Center at Bayer Japan in May 2020 and was involved in programs such as the startup support program “Kansai Life Science Accelerator Program and a shared lab/office space, CoLaborator Kobe.
Since May 2023, he has been involved in fostering the life science innovation ecosystem and promoting overseas collaboration as Executive Life Science Strategist at Mitsui Fudosan Co., Ltd. and President & COO at LINK-J.
PhD in Pharmaceutical Sciences from the University of Tokyo, R.Ph., and MBA from University of California, San Diego.
Felix co-founded Integrated Bio after serving as an NIH-funded independent fellow at the Broad Institute of MIT and Harvard. He brings over a decade of experience at the intersection of AI and biology. His research has been published in over 30 scientific papers and in leading journals such as Nature, Science, and Cell, and he has pioneered the use of AI approaches for discovering novel small-molecule compounds, including senolytics and antibiotics.
As Head of Operations at KORTUC INC., Seiko Kuroda is bringing a Japan-born cancer treatment technology to the global stage. She led the establishment of KORTUC’s U.S. operations as the company expanded its clinical development internationally. She now leads fundraising, business development, and planning for product launches in the U.S. and Europe.
Thanh Nguyen, PhD, is an Associate Professor of Emergency Medicine at UNMC and a healthcare entrepreneur committed to decentralizing medical care and closing global health equity gaps. Leveraging frontline clinical experience since 2010, Dr. Nguyen champions open-source design and advanced technologies like AI and 3D printing to create scalable, low-cost medical solutions. He is the founder of Open-MediciNE (2020), an initiative enabling low-resource communities to produce off-grid medical equipment locally. As a founding partner of UMD Inc. (2021), HemaGlobal (2024), and FlySwift Studios (2026), Dr. Nguyen combines commercial agility with humanitarian engineering to expand healthspan and transform global healthcare delivery.
Mainul Mondal is the Co-Founder and CEO at Ellipsis Health. Driven by his mother’s health journey and the power of empathetic care, Mainul founded Ellipsis Health to transform healthcare through conversational AI. Ellipsis Health’s pioneering vocal biomarker technology, backed by extensive research, led to the creation of Sage, an emotionally intelligent AI voice agent addressing staffing shortages and enhancing cost containment for large hospital systems, health plans, and specialty care managers. As a Nasdaq Milestone Maker and Rockefeller Fellow at the Public Health Institute, Mainul is a recognized leader shaping a future where technology and empathy converge to make quality care accessible to everyone.
Samet Yildirim is a biotech entrepreneur and business executive focused on
translating breakthrough stem cell and regenerative biology into scalable
therapeutic and commercial platforms. He is the Co-Founder and Chief Business
Officer of HexemBio, where he leads strategy, partnerships, and financing for a
longevity-focused biotechnology company. Prior to HexemBio, Samet founded and
built a stem cell technology startup from the ground up, advancing its technology
from early development through global scale-up and ultimately to a successful
acquisition. He previously spent nearly a decade at Boehringer Ingelheim, where
he served as Global Head of Technology and Innovation and led the development
of next-generation manufacturing platforms and digital CMC technologies for the
company’s biopharma business unit. Samet holds a Master of Business and Science
from Keck Graduate Institute and a Master of Science in Biophysics from Ankara
University.
Vik Kashyap is the Founder & CEO of Toi Labs, developer of TrueLoo, an AI-powered health monitoring platform that transforms the toilet into a source of longitudinal health data. Toi Labs’ work has been supported by the U.S. National Institutes of Health and leading global bathroom companies, including TOTO and Sloan. Vik previously developed a novel treatment approach for inflammatory bowel disease, co-authored research published in Science Translational Medicine, and is a graduate of Harvard University.
Paul Grimm is CEO and Board Member of Myoptechs, a pediatric ophthalmic medical device company developing patented soft contact lens and spectacle technologies designed to slow the progression of myopia in children. He has more than 20 years of commercial and executive leadership experience across medical devices, pharmaceuticals, medical nutrition, and consumer health, including leadership roles at Abbott Laboratories and Medicis Pharmaceutical. Over the past six years, Paul has focused on ophthalmology, including the development and commercialization of innovative early-stage technologies. At Myoptechs, he leads the company’s strategy, financing, clinical development, and strategic partnerships.
Ziad Ali is the co-founder and CEO of Clairvoyance, a Stanford spinout developing wearable biomagnetic sensing technology for health monitoring and medical devices. Ziad earned his PhD in Electrical Engineering from Stanford University under Prof. Ada Poon, where he developed the magnetic pixel technology powering Clairvoyance’s sensors. His work has been supported by the Knight-Hennessy Scholarship, National Science Foundation GRFP award, and the Wu Tsai Neurosciences Institute.
Chen-Sen (“Samson”) Wu, JD, MD, is an attorney-physician with 20+ years of legal, medical affairs, and commercial launch experience across global pharma, med tech, and diagnostics companies, including multiple General Counsel roles at GE HealthCare, as Vice President of Global Medical Affairs at GSK leading 300+ professionals, and currently as General Counsel as well as Interim Vice President of Strategy and Value Enablement at Cepheid (a Danaher company). He combines broad legal, crisis management, and organizational change leadership – including championing adoption of legal AI technology (see https://lnkd.in/p/gMpg4d6s) – with deep domain expertise in healthcare regulations, product launches, medical and scientific affairs, mass tort / products liability litigation, and cross-border anti-bribery and anti-corruption (ABAC) investigations as part of a 3-year assignment to Singapore. He has served 10+ years on non-profit boards including as Secretary and on Audit, Governance, and Long-Range Planning committees for an academic center for Duke University students and faculty, a K-12 private school, organizations combatting human trafficking, and a clinic providing healthcare to underserved communities. Samson received his degrees from Yale Law School, Duke University School of Medicine, and Stanford University.
Toshihiro Maeda serves as Chief Operating Officer (COO) of Nxera Pharma Co., Ltd. and Representative Director and President of Nxera Pharma Japan Co., Ltd. Prior to joining Nxera Pharma, he served as a Business Unit Head at Bristol Myers Squibb (BMS) in Japan, where he led the post-merger integration following the acquisition of Celgene and drove commercialization strategy. Before joining BMS, he held roles at Merck & Co. (MSD in Japan), focusing on partnerships and commercialization in the oncology and diabetes therapeutic areas in both Japan and the United States. He brings extensive experience in global leadership and pharmaceutical commercialization. He joined Nxera Pharma as COO in December 2023.
Yuta Inokuchi is Chief Operating Officer of SOLA Biosciences Japan, the Tokyo-based subsidiary of Boston-headquartered SOLA Biosciences Inc. The company is developing AAV-based gene therapies for neurodegenerative diseases. Its lead program, SOL-257, is in preclinical development for ALS and is supported by a subsidy from AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem. Yuta heads the Japanese subsidiary and leads program management for research and development, which SOLA runs as a single integrated effort across its US and Japan teams. Before joining SOLA, he spent more than ten years at L.E.K. Consulting, where he was a Partner and Head of Japan, advising pharmaceutical, biotech, and medtech companies and their investors on strategy. He studied molecular biology and neuroscience at International Christian University and the University of Tokyo.
Physician-scientist and academic leader specializing in human induced pluripotent stem cell(iPSC)-based
disease modeling, drug discovery, precision medicine, and clinical translation. His work has established a
continuum from the development of human iPSC-derived neuronal models and phenotypic screening
technologies to the identification of therapeutic targets, clinical evaluation of iPSC-derived drug candidates,
and integration of artificial intelligence and machine learning with human disease-model data.
He has extensive experience in connecting stem cell science with clinical medicine, pharmaceutical
development, industry, and international scientific communities.
LEADERSHIP AT THE INTERFACE OF STEM CELL SCIENCE AND SOCIETY
Website: https://inoue.cira.kyoto-u.ac.jp/en/
Dr. Stubbs is an Assistant Professor and Director of Translational Science at The Buck Institute for Research on Aging, where her work focuses on researching ketone esters for healthy aging. She completed her PhD in Metabolic Physiology at the University of Oxford. Whilst completing her studies she was a two-time World Champion in lightweight rowing on Team Great Britain. Brianna spent two years as Research Lead at a San Francisco start-up, where she launched the world’s first ketone ester consumer product and received $6M of funding from the US Special Operations Command to investigate exogenous ketone impacts on performance in extreme environments. Since moving to The Buck, she received the inaugural NIA Research and Entrepreneurial Development Immersion K01 award, launched a second consumer product and co-founded a ketone-therapeutic company. In 2023, Dr Stubbs co-established the Buck Clinical Geroscience Unit to run the first onsite clinical studies at The Buck.
Masayuki joined Deloitte Touche Tohmatsu LLC in 2007. From 2010, he took part in the second founding of Deloitte Tohmatsu Venture Support, establishing its Silicon Valley office in 2015 and leading its expansion to 260 employees across five global locations as COO. He supported numerous Japanese companies in digital and service transformation, and held roles including COO/Partner at Deloitte Tohmatsu Venture Support and Emerging Growth Leader at Deloitte Private Asia Pacific.
In June 2025, he joined Sompo Holdings, Inc. as Group Co-CDO and Executive Vice President. Leveraging his extensive track record and robust global network, he leads the group’s digital, data, and AI initiatives.
Hirokazu Shimoda joined the Ministry of Economy, Trade and Industry (METI, Japan) in 1999, and he was engaged in promoting various industries, including IT, cybersecurity, biotechnology and cell and gene therapy, healthcare, and the service sector. From 2016 to 2020, he served as Senior Director of the San Francisco Office of the Japan External Trade Organization (JETRO), concurrently holding a position as a Fellow at the World Economic Forum’s Center for the Fourth Industrial Revolution.
After returning to Japan, he held key positions at METI, including Director of the Information Systems Division and Director of the Bio-Industry Division, where he was responsible for biotechnology industry policy. Since July 2025, he has been serving as a Senior Director at the Japan Agency for Medical Research and Development (AMED), overseeing the practical application of research outcomes and the promotion of the drug development ecosystem.
Joe Heanue is the CEO of Triple Ring, where he is responsible for the firm’s overall vision, culture, and technical excellence. Drawing on a background in physics, engineering, and entrepreneurship, he builds multidisciplinary teams, leads growth partnerships with large corporations, and steers high-value R&D efforts across the healthcare technology landscape.
Hiroki Sugita is a partner in Orrick’s Tokyo Office and a member of the M&A and Private Equity Group. He works on a wide range of cross-border transactions including mergers and acquisitions, joint ventures, emerging companies and venture capital transactions, and private equity investment especially in Japan, the United States, Europe and Asia.
Hiroki has extensive experience and deep expertise in the life sciences sector and provides support to clients in a wide range of areas, including biotechnology, pharmaceuticals, digital health, research, laboratories, medical devices and diagnostic tools.
He also has extensive experience in fund formation, real estate and various types of finance transactions.
Hiroki has a deep understanding of clients’ needs from his secondment experience with a U.S. investment bank in 2005 and a Japanese major trading house from 2012 to 2014.
Joe Alexander Jr., MD, PhD, FACC, is Senior Vice President and Director of Medical & Health
Informatics at NTT Research, where he leads Precision Cardiology and development of a
cardiovascular bio-digital twin platform. A physician-scientist and biomedical engineer trained at
Johns Hopkins, with clinical and research fellowships at Albert Einstein College of Medicine and
Kyushu University, he brings deep expertise in cardiovascular dynamics, modeling and
simulation, and translational medicine. His career spans academic medicine, more than 18 years
of leadership roles at Pfizer across R&D, medical affairs, clinical technology, and business
development, and current work building strategic partnerships to advance data-driven,
personalized cardiovascular care. He is an experienced innovator with a strong publication
record and a practical focus on translating complex biomedical technologies into clinically and
commercially meaningful solutions.
Dr. Jianyu (Daniel) Wu is a biologist by training with a background in stem cell research. Following his postdoctoral fellowship at Yale University, Dr. Wu joined Insilico Medicine as a Biology Project Leader in R&D, where he spearheaded early-stage drug discovery across immunology, oncology, and CNS diseases. Notably, he led the successful nomination of a Preclinical Candidate (PCC) that subsequently received FDA IND approval.
In May 2023, Dr. Wu transitioned to the Business Development team. He now oversees external collaborations for Insilico’s proprietary AI drug discovery platform, AI drug discovery collaboration as well as the out-licensing of the internal pipeline in APAC region including Japan and South Korea. He has been driving and closed multiple AI drug discovery collaboration with total deal value approximal $3 billion and being a key contributor to multiple global pharmaceutical deals.
Linkedin: www.linkedin.com/in/danieljwu316
Gregg Yoshito Shibata (柴田 義人) is a 25-year healthcare veteran with deep expertise navigating U.S. health plans and the healthcare venture ecosystem. He leads the strategic investment program at Blue Shield of California, one of California’s largest nonprofit health plans, where he keeps one foot in the health plan world and one foot in the venture ecosystem – building collaborative and commercial partnerships between internal business leaders and innovative startups.
As an investor, Gregg manages a portfolio spanning direct investments and venture funds across multiple venture-firm partners. As a partnership enabler, he has driven more than 38 commercial contracts, delivering over $100M in revenue to startup partners over his career. His earlier career includes leadership roles at Echo Health Ventures, Quil Health (a joint venture between Independence Blue Cross and Comcast), and Cambia Health Solutions.
Since 2023, Gregg has applied this experience to help Japanese enterprises, entrepreneurs, and investors enter the U.S. healthcare market, advising on a variety of topics such as reimbursement strategy, go-to-market approaches, and commercialization pathways. He is an Advisor to Kicker Ventures and has collaborated on a number of projects with JETRO, METI, Mitsubishi Corporation, Nozomi MedAlliance, and TheraNova around accelerator programming, reimbursement education, and startup mentoring.
A third-generation Japanese American, Gregg graduated from UC Berkeley with a degree in Japanese History. He then immersed himself in Japanese culture through the JET Program, spending four years teaching in Kitadaito, Okinawa (沖縄県北大東村). He returned to the U.S. in 2001 to build his healthcare career but continues to return to Japan to visit family, friends, and former students, and actively supports Japanese and Japanese American cultural exchange through local community organizations.
Paul Gadiock is a Partner at McDermott Will & Schulte’s San Francisco’s office. He leverages his firsthand experience at the Food and Drug Administration (FDA) to provide life sciences, healthcare and other domestic and foreign FDA-regulated companies with practical, strategic counsel at every phase of the product life cycle. Paul supports medical device, digital therapeutic, and biopharma companies, drug compounders, software as a medical device (SaMD) and clinical decision support (CDS) developers and their investors on FDA regulatory and due diligence matters, delivering premarket and postmarket regulatory guidance to maximize business outcomes.
Previously, Paul was a member of the senior leadership team at the FDA’s Center for Devices and Radiological Health, where he advised agency officials on issues related to the regulatory scope of the FDA’s policies, programs, regulations, and legislation affecting the medical device industry. He also collaborated with the Office of Inspector General (OIG) and Government Accountability Office(GAO) on analyses, investigations and oversight of major national programs. In addition to his government experience, Paul provides a commercially minded approach rooted in real-world experience as a former business development executive at a national diagnostic biotechnology company.
Dan Belsky is Associate Professor of Epidemiology at the Columbia University Mailman School of Public in the Robert N Butler Columbia Aging Center, where he directs the Center’s Geroscience Computational Core. His group develops methods to quantify the pace and progress of biological aging in young, midlife, and older adult humans and applies these methods in epidemiological studies and clinical trials to identify opportunities for intervention to increase healthy lifespan. Dan has been recognized as a leader in his field with the Academy of Behavioral Medicine’s Neal Miller New Investigator Award and the American Federation for Aging Research’s Vincent Cristofalo Rising Star Award. He is a fellow of the Academies of Behavioral Medicine and Geroscience. His work is supported by the US National Institute on Aging, the Advanced Research Projects Agency for Health (ARPA-H), the Canadian Institute for Advanced Research, and the American Federation for Aging Research (AFAR), among other sources. He is co-director of the AFAR FAST Initiative and a member of the Scientific Advisory Boards of AFAR, the Biomarkers of Aging Consortium, and X-Prize Healthspan. He is an inventor of the Pace of Aging method and the DunedinPACE epigenetic clock. Since 2020, he has been named an ISI highly-cited researcher.
We welcome your application to pitch your company at the Conference.
Application Deadline: September 7, 2026
We are seeking early to mid-stage companies from the following sectors:
There are no application fees, but selected companies will be responsible for their own travel and lodging costs and asked to pay a $500 per company program fee that can be applied toward 2027 corporate membership in Japan Society. Applications will be evaluated based on alignment with the program theme, interest in the Japanese market, timely response, and commitment to full participation. We will prioritize applications from companies that are offering solutions in the areas of healthspan, longevity, and age-related diseases.
Early submission is encouraged as space is limited.
To apply or learn more, please contact:
Stay up to date on upcoming Japan Society events and activities.